As Dividend Stocks Go, Philip Morris Is Expensive: Here Is a Cheaper Pick

Philip Morris is expensive when valued by its free cash flow, but another dividend titan is cheaper.

Jun 7, 2014 at 10:00AM

Every portfolio should have a dividend stock at its core to provide a degree of diversification and stability.

The best dividend stocks are usually found within the consumer goods sector as the sector's defensive nature means that cash flows are predictable. A predictable cash flow creates the perfect environment to support a sustainable dividend payout.

Philip Morris (NYSE:PM) is the perfect dividend stock. The company is one of the most profitable in the world and offers an attractive 4.5% dividend yield.

However, is now the time to buy Philip Morris, or should you wait for a better price?

Only bad prices
The Godfather of value investing, Benjamin Graham, stated that there are no bad assets, only bad prices. Philip Morris is a good asset, there is no doubt about that, but how do we know if the company is trading at a bad price or a good one?

Well, for a start we can compare the company to its peers, for example, Altria, Reynolds American, and Lorillard, which trade at forward P/Es of 14.7, 16.5, and 16.6, respectively, in comparison to Philip Morris' forward P/E of 15.3.

This in itself is not enough as Philip Morris is an international tobacco company, therefore we should compare it to international peers, not domestic peers like those above. What's more, Lorillard and Reynolds are currently in the midst of merger talks, so they have skewed valuations.

An appropriate valuation
We could spend all day comparing Philip Morris to its peers using simple valuation metrics and not really get anywhere. However, there is one key metric that needs to be taken into account above the rest--the fact that Philip Morris is the single most profitable company in the world in terms of free cash flow as a percentage of revenue.

Specifically, Philip Morris converts 29.1% of its revenue to free cash flow, followed by Pfizer (NYSE:PFE) at 26.4%. British American comes in fourth, converting 24.6% of its revenue, and Imperial Tobacco comes in ninth. Altria, Reynolds and Lorillard do not feature in the top 20.

Furthermore, Philip Morris has hiked its dividend payout 104% since 2008 and has repurchased a total of 25.6% of its shares since 2008.

These are all impressive metrics and lead me to conclude that Philip Morris should not be valued on earnings or compared to its tobacco peer group, but instead compared on cash flow to other free cash flow behemoths.

So in comparison with free cash flow leaders Johnson and Johnson (NYSE:JNJ) as well as Pfizer, how does Philip Morris compare?

Philip Morris' free cash flow was $8.3 billion for 2013 and the company is currently worth $136 billion, or 16.4 times its annual free cash flow.

Pfizer's free cash flow was $16.3 billion for 2013 and the company is currently worth $189 billion, or 11.6 times its annual free cash flow.

Johnson and Johnson's free cash flow was $13.8 billion for 2013 and the company is currently worth $286 billion, or 20.7 times its annual free cash flow .

So then, in comparison with its free cash flow peers, Philip Morris looks to be trading at an average valuation.

Foolish summary
All in all, Philip Morris' defensive nature and attractive dividend yield make the company the perfect 'back bone' for any portfolio.

However, it would appear that at current levels, when taking into account the company's free cash flow, Philip Morris looks a bit expensive in comparison with peer Pfizer.

Although it only offers a dividend yield of 3.5% at present, 1% below that offered by Philip Morris, Pfizer looks more attractive on a valuation basis and capital growth could make up for the lack of dividend income.


Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Rupert Hargreaves owns shares of Altria Group. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information